Nestler, S.
Peschel, C.
Horstmann, A. H.
Vahlensieck, W.
Fabry, W.
Neisius, A.
Article History
Received: 30 June 2022
Accepted: 24 September 2022
First Online: 1 October 2022
Change Date: 25 January 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s11255-023-03469-5
Declarations
:
: S Nestler works as an advisor/author for Dermapharm, Strathmann, Abbvie, GlaxoSmithKline. S Peschel and AH Horstmann are employees of Strathmann GmbH & Co. KG. W Vahlensieck works as advisor/author for Apogepha, Bene, Bionorica, Strathmann, Fresenius, Infectopharm, Medice, Perrigo, Repha. W Fabry have no conflicts of interest. A Neisius works as an advisor/author for MSD, Janssen, AstraZeneca, Ispen, Amgen, Roche, GlaxoSmithKline, Optimed, Boston Scientific.
: This study was conducted in compliance with the ICH Guideline E6 (R1) on Good Clinical Practice and registered under EudraCT no. 2010-020882-25. Several ethic committees were involved, including a leading committee in Berlin and local ethic committees in regions with participating centres. Informed consent was obtained by all patients.